News

Sanofi: Timeout for Campath
Enlarge image

BusinessFranceEU

Sanofi: Timeout for Campath

21.08.2012 - Sanofi withdraws a cancer drug from the markets and aims for a relaunch in multiple sclerosis.

Sanofi is withdrawing its cancer drug Campath from the markets. The pharma plans to commercialise the antibody under a different name and dosing regime for multiple sclerosis – a much more lucrative indication.

The development of Campath-1H, also known under its generic name alemtuzumab, as a successful drug took years. The anti-CD52 antibody was thought to cure rheumatoid arthritis in the beginning of the 90s but failed expectations. Since 2001, it has finally been approved for chronic lymphocytic leukaemia (CLL). Since then it also washes some money into Sanofi’s subsidiary Genzyme Corp. from Cambridge (USA). But revenues have been decling over the past years. Therefore Sanofi is now aiming for fresh money and a higher pricing. In a move to prevent off-label use the drug has now been pulled from European (in mid-August) and US markets (in early September) markets.

In both regions the market authorisation applications (MAAs) for a use in multiple sclerosis are pending. According to the pharma company clearing the market should ensure that „alemtuzumab is exclusively received and used in the ongoing clinical trials.“ Obviously, Sanofi thinks that a widely merchandised drug could jeopardise these trials. Alemtuzumab awaits its repeated market entry under the name Lemtrada. However, the German society for haematology and oncology (DGHO) criticises Sanofi for playing one group of patients against another. Sanofi responded that all leukaemia patients (so far about 4.000) will benefit from free-of-charge programmes that make sure that all patients receive their much needed medicine. In Germany, according to the DGHO, these programmes run so far quite smoothly even if they mean an increased bureaucratic effort.

http://www.european-biotechnology-news.com/news/news/2012-03/sanofi-timeout-for-campath.html

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.50 EUR12.78%
  • BIOCARTIS GROUP NV (B)7.57 EUR7.53%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%

FLOP

  • NICOX (F)11.57 EUR-8.61%
  • KAROLINSKA (S)7.55 SEK-4.43%
  • AB SCIENCE (F)14.20 EUR-4.05%

TOP

  • PROTHENA PLC (IE)53.17 USD31.1%
  • THERAMETRICS (CH)0.05 CHF25.0%
  • FLAMEL TECHNOLOGIES (F)12.49 USD24.9%

FLOP

  • MOLOGEN (D)1.50 EUR-40.2%
  • ALLERGY THERAPEUTICS (UK)19.50 GBP-21.2%
  • SAREUM HOLDINGS (UK)0.64 GBP-21.0%

TOP

  • KARO BIO (S)28.70 SEK1693.8%
  • NICOX (F)11.57 EUR515.4%
  • SAREUM HOLDINGS (UK)0.64 GBP156.0%

FLOP

  • BB BIOTECH (D)45.22 EUR-84.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.64 SEK-79.6%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 22.07.2016